靶向ROR1的抗体药物偶联物huXBR1-402-G5-PNU有效作用于ROR1阳性白血病
本文报道一种人源化抗ROR1抗体药物偶联物huXBR1-402-G5-PNU,将新型抗ROR1抗体huXBR1-402与高活性蒽环类衍生物PNU连接。体外对增殖性ROR1阳性恶性细胞有细胞毒性,并在多种人ROR1阳性白血病小鼠移植模型中抑制白血病增殖、延长生存;其BCL2依赖性细胞毒性可与BCL2抑制剂维奈克拉联合策略协同。
要点
- huXBR1-402-G5-PNU体外对增殖性ROR1阳性恶性细胞有细胞毒性
- 多种人ROR1阳性白血病小鼠模型中抑制白血病增殖并延长生存
- 其BCL2依赖性细胞毒性可与维奈克拉联合治疗策略结合
核心结论
- huXBR1-402-G5-PNU在治疗ROR1阳性血液恶性肿瘤方面提供了有力的临床前证据。
研究设计与样本
- 本文描述一种人源化、first-in-class抗ROR1抗体药物偶联物huXBR1-402-G5-PNU,将新型抗ROR1抗体huXBR1-402与高活性蒽环类衍生物PNU连接。
- 研究包括体外细胞毒实验及多种人ROR1阳性白血病小鼠移植模型。
主要发现
- huXBR1-402-G5-PNU体外对增殖性ROR1阳性恶性细胞有细胞毒性。
- 在多种人ROR1阳性白血病小鼠移植模型中,huXBR1-402-G5-PNU抑制白血病增殖并延长生存。
- huXBR1-402-G5-PNU的BCL2依赖性细胞毒性可通过与BCL2抑制剂维奈克拉联合治疗策略加以利用。
临床怎么用
- ROR1在正常成人组织表达有限,而在套细胞淋巴瘤、伴t(1;19)(q23;p13)易位的急性淋巴细胞白血病和慢性淋巴细胞白血病恶性细胞表面过表达,使其成为抗体药物偶联物治疗的有吸引力的靶点。
- 临床前数据支持进一步开发huXBR1-402-G5-PNU用于ROR1阳性血液恶性肿瘤,并提示与维奈克拉联合的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-drug conjugates directed against tumor-specific targets have allowed targeted delivery of highly potent chemotherapy to malignant cells while sparing normal cells. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein with limited expression on normal adult tissues and is overexpressed on the surface of malignant cells in mantle cell lymphoma, acute lymphocytic leukemia with t(1;19)(q23;p13) translocation, and chronic lymphocytic leukemia. This differential expression makes ROR1 an attractive target for antibody-drug conjugate therapy, especially in malignancies such as mantle cell lymphoma and acute lymphocytic leukemia, in which systemic chemotherapy remains the gold standard. Several preclinical and phase 1 clinical studies have established the safety and effectiveness of anti-ROR1 monoclonal antibody-based therapies. Herein we describe a humanized, first-in-class anti-ROR1 antibody-drug conjugate, huXBR1-402-G5-PNU, which links a novel anti-ROR1 antibody (huXBR1-402) to a highly potent anthracycline derivative (PNU). We found that huXBR1-402-G5-PNU is cytotoxic to proliferating ROR1+ malignant cells in vitro and suppressed leukemia proliferation and extended survival in multiple models of mice engrafted with human ROR1+ leukemia. Lastly, we show that the B-cell lymphoma 2 (BCL2)-dependent cytotoxicity of huXBR1-402-G5-PNU can be leveraged by combined treatment strategies with the BCL2 inhibitor venetoclax. Together, our data present compelling preclinical evidence for the efficacy of huXBR1-402-G5-PNU in treating ROR1+ hematologic malignancies.
引用
- Hu EY, Do P, Goswami S, et al. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Adv. 2021. PMID: 34424320. doi:10.1182/bloodadvances.2020003276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。